Last mentioned: Jul 7, 2026
Across the most recent 5 stories covering RMC-6236 — 60% negative, 40% neutral sentiment, averaging 6.2/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived. See something wrong on this page? Report a data issue.
Lead Plaintiff Deadline
Deadline for investors to move for appointment as lead plaintiff in the securities class action.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
Securities Class Action Announced
Hagens Berman announces the filing of a federal securities class action lawsuit and begins soliciting investor clients.
Stock Crash and Corrective Disclosure
Erasca shares plunge 48% on news that Revolution Medicines accused the company of patent infringement and that a trial patient died a month after receiving ERAS-0015. Class period ends.
Alleged Misleading Statements
Erasca reportedly assured investors of ERAS-0015's IP protection and made dose-equivalence comparisons to RevMed's RMC-6236.
Axsome full-year 2025 results
Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
Revolution Medicines mid-2025 data readout
RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
Class Period Begins
Start of the period during which Erasca allegedly made misleading statements that inflated its stock price.
A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
A securities fraud lawsuit alleges Erasca misled investors about IP and drug safety, triggering a 48% stock drop. Investors have until August 10, 2026 to seek lead plaintiff status.
Following a patient death in its ERAS-0015 trial, Erasca faces allegations it withheld risks, leading to a 48% stock collapse. The case underscores threats to clinical transparency.
Revolution Medicines' patent infringement claim and a patient death have derailed Erasca's lead candidate, cutting its valuation by $2.8B. The biotech now faces a class action over alleged misrepresentations.
Source: Globenewswire_fr · Benzinga